Boulevard starts up with $65M to pursue targeted autoimmune drugs
admin Boulevard Bio, a newly formed biotechnology startup, officially commenced operations on Wednesday, announcing a robust...
pharma
Ying Huang Appointed CEO of K2 Therapeutics, Spearheading a $50 Million Seed-Funded Venture to Globalize Chinese Biotech Innovation
Ying Huang, the esteemed former CEO who steered Legend Biotech to commercial triumph with the...
Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease
Epicrispr Biotechnologies, a burgeoning player in the genetic medicine landscape, has successfully closed a $90...
Scribe Therapeutics Pioneers Epigenetic Silencing for Cardiovascular Disease, Navigating a Cautious Gene Editing IPO Market
In a striking juxtaposition of industrial heritage and futuristic biotechnology, Scribe Therapeutics, a burgeoning gene...
Jazz Pharmaceuticals Acquires Actio Biosciences in $820 Million Upfront Deal, Bolstering Rare Epilepsy Pipeline
Jazz Pharmaceuticals has announced its acquisition of Actio Biosciences in an upfront deal valued at...
Sionna Therapeutics Shares Plummet After Key Cystic Fibrosis Drug Fails to Demonstrate Additive Benefit with Vertex’s Trikafta
San Diego, CA — August 10, 2026 — Sionna Therapeutics experienced a dramatic collapse in...
The Strategic Imperative of Proactive Regulatory Operations in Pharmaceutical Submissions
The pharmaceutical industry, a crucible of innovation and a beacon of hope for countless patients,...
LifeMine Therapeutics Secures $263 Million to Propel Novel Fungal-Derived Immunosuppressant for Organ Transplantation Towards Advanced Clinical Trials
LifeMine Therapeutics, a pioneering biotechnology firm spearheading innovation in natural product drug discovery under the...
‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
The biopharmaceutical sector witnessed a dynamic period marked by significant clinical advancements, strategic corporate maneuvers,...
Latigo Biotherapeutics Secures $345.6 Million in Landmark IPO, Poised to Challenge Giants in Non-Opioid Pain Market Amidst Biotech Resurgence
Pain drugmaker Latigo Biotherapeutics successfully completed its initial public offering (IPO) on Thursday, August 7,...
